nach oben

Erschienen in:

01.10.2013 | Article

Modulation of p75^NTR prevents diabetes- and proNGF-induced retinal inflammation and blood–retina barrier breakdown in mice and rats

verfasst von: Barbara A. Mysona, Mohammed M. H. Al-Gayyar, Suraporn Matragoon, Mohammed A. Abdelsaid, Mona F. El-Azab, H. Uri Saragovi, Azza B. El-Remessy

Erschienen in: Diabetologia | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Diabetic retinopathy is characterised by early blood–retina barrier (BRB) breakdown and neurodegeneration. Diabetes causes imbalance of nerve growth factor (NGF), leading to accumulation of the NGF precursor (proNGF), as well as the NGF receptor, p75 neurotrophin receptor (p75^NTR), suggesting a possible pathological role of the proNGF–p75^NTR axis in the diabetic retina. To date, the role of this axis in diabetes-induced retinal inflammation and BRB breakdown has not been explored. We hypothesised that modulating p75^NTR would prevent diabetes- and proNGF-induced retinal inflammation and BRB breakdown.

Methods

Diabetes was induced by streptozotocin in wild-type and p75^NTR knockout (p75KO) mice. After 5 weeks, the expression of inflammatory mediators, ganglion cell loss and BRB breakdown were determined. Cleavage-resistant proNGF was overexpressed in rodent retinas with and without p75^NTR short hairpin RNA or with pharmacological inhibitors. In vitro, the effects of proNGF were investigated in retinal Müller glial cell line (rMC-1) and primary Müller cells.

Results

Deletion of p75^NTR blunted the diabetes-induced decrease in retinal NGF expression and increases in proNGF, nuclear factor κB (NFκB), p-NFκB and TNF-α. Deletion of p75^NTR also abrogated diabetes-induced glial fibrillary acidic protein expression, ganglion cell loss and vascular permeability. Inhibited expression or cleavage of p75^NTR blunted proNGF-induced retinal inflammation and vascular permeability. In vitro, proNGF induced p75^NTR-dependent production of inflammatory mediators in primary wild-type Müller and rMC-1 cultures, but not in p75KO Müller cells.

Conclusions/interpretation

The proNGF–p75^NTR axis contributes to retinal inflammation and vascular dysfunction in the rodent diabetic retina. These findings underscore the importance of p75^NTR as a novel regulator of inflammation and potential therapeutic target in diabetic retinopathy.

Nur mit Berechtigung zugänglich

Klein R, Klein BE, Moss SE, Wong TY (2006) The relationship of retinopathy in persons without diabetes to the 15-year incidence of diabetes and hypertension: Beaver Dam Eye Study. Trans Am Ophthalmol Soc 104:98–107PubMedPubMedCentral

Antonetti DA, Barber AJ, Bronson SK et al (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55:2401–2411PubMedCrossRef

Fletcher EL, Phipps JA, Wilkinson-Berka JL (2005) Dysfunction of retinal neurons and glia during diabetes. Clin Exp Optom 88:132–145PubMedCrossRef

Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW (2002) Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 47(Suppl 2):S253–S262PubMedCrossRef

Ali TK, Al-Gayyar MM, Matragoon S et al (2011) Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia 54:657–668PubMedCrossRef

Al-Gayyar MM, Matragoon S, Pillai BA, Ali TK, Abdelsaid MA, El-Remessy AB (2011) Epicatechin blocks pro-nerve growth factor (proNGF)-mediated retinal neurodegeneration via inhibition of p75 neurotrophin receptor expression in a rat model of diabetes [corrected]. Diabetologia 54:669–680PubMedCrossRef

Ali TK, Matragoon S, Pillai BA, Liou GI, El-Remessy AB (2008) Peroxynitrite mediates retinal neurodegeneration by inhibiting NGF survival signal in experimental and human diabetes. Diabetes 57:889–898PubMedCrossRef

Hempstead BL (2009) Commentary: Regulating proNGF action: Multiple targets for therapeutic intervention. Neurotox Res 16:255–260PubMedCrossRefPubMedCentral

Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science 294:1945–1948PubMedCrossRef

10.

Harrington AW, Leiner B, Blechschmitt C et al (2004) Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci U S A 101:6226–6230PubMedCrossRefPubMedCentral

11.

Baker SJ, Reddy EP (1998) Modulation of life and death by the TNF receptor superfamily. Oncogene 17:3261–3270PubMedCrossRef

12.

Cragnolini AB, Friedman WJ (2008) The function of p75NTR in glia. Trends Neurosci 31:99–104PubMedCrossRef

13.

Ibanez CF (2002) Jekyll-Hyde neurotrophins: the story of proNGF. Trends Neurosci 25:284–286PubMedCrossRef

14.

Roux PP, Barker PA (2002) Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 67:203–233PubMedCrossRef

15.

Lebrun-Julien F, Bertrand MJ, de Backer O et al (2010) ProNGF induces TNFalpha-dependent death of retinal ganglion cells through a p75NTR non-cell-autonomous signaling pathway. Proc Natl Acad Sci U S A 107:3817–3822PubMedCrossRefPubMedCentral

16.

Nykjaer A, Lee R, Teng KK et al (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427:843–848PubMedCrossRef

17.

Frade JM (2005) Nuclear translocation of the p75 neurotrophin receptor cytoplasmic domain in response to neurotrophin binding. J Neurosci Off J Soc Neurosci 25:1407–1411CrossRef

18.

Kanning KC, Hudson M, Amieux PS, Wiley JC, Bothwell M, Schecterson LC (2003) Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. J Neurosci Off J Soc Neurosci 23:5425–5436

19.

Fortini ME (2002) Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol 3:673–684PubMedCrossRef

20.

Zampieri N, Xu CF, Neubert TA, Chao MV (2005) Cleavage of p75 neurotrophin receptor by alpha-secretase and gamma-secretase requires specific receptor domains. J Biol Chem 280:14563–14571PubMedCrossRef

21.

Kenchappa RS, Zampieri N, Chao MV et al (2006) Ligand-dependent cleavage of the P75 neurotrophin receptor is necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons. Neuron 50:219–232PubMedCrossRef

22.

Jung KM, Tan S, Landman N et al (2003) Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem 278:42161–42169PubMedCrossRef

23.

Carter BD, Kaltschmidt C, Kaltschmidt B et al (1996) Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. Science 272:542–545PubMedCrossRef

24.

Bhakar AL, Roux PP, Lachance C, Kryl D, Zeindler C, Barker PA (1999) The p75 neurotrophin receptor (p75NTR) alters tumor necrosis factor-mediated NF-kappaB activity under physiological conditions, but direct p75NTR-mediated NF-kappaB activation requires cell stress. J Biol Chem 274:21443–21449PubMedCrossRef

25.

Lee KF, Li E, Huber LJ et al (1992) Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell 69:737–749PubMedCrossRef

26.

Pagadala PC, Dvorak LA, Neet KE (2006) Construction of a mutated pro-nerve growth factor resistant to degradation and suitable for biophysical and cellular utilization. Proc Natl Acad Sci U S A 103:17939–17943PubMedCrossRefPubMedCentral

27.

Matragoon S, Al-Gayyar MM, Mysona BA et al (2012) Electroporation-mediated gene delivery of cleavage-resistant pro-nerve growth factor causes retinal neuro- and vascular degeneration. Mol Vis 18:2993–3003PubMedPubMedCentral

28.

LeSauteur L, Wei L, Gibbs BF, Saragovi HU (1995) Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. J Biol Chem 270:6564–6569PubMedCrossRef

29.

Nadal-Nicolas FM, Jimenez-Lopez M, Sobrado-Calvo P et al (2009) Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas. Investig Ophthalmol Vis Sci 50:3860–3868CrossRef

30.

Al-Shabrawey M, Rojas M, Sanders T et al (2008) Role of NADPH oxidase in retinal vascular inflammation. Investig Ophthalmol Vis Sci 49:3239–3244CrossRef

31.

Sarthy VP, Brodjian SJ, Dutt K, Kennedy BN, French RP, Crabb JW (1998) Establishment and characterization of a retinal Muller cell line. Investig Ophthalmol Vis Sci 39:212–216

32.

Mysona B, Dun Y, Duplantier J, Ganapathy V, Smith SB (2009) Effects of hyperglycemia and oxidative stress on the glutamate transporters GLAST and system xc- in mouse retinal Muller glial cells. Cell Tissue Res 335:477–488PubMedCrossRefPubMedCentral

33.

Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783–791PubMedCrossRefPubMedCentral

34.

Kern TS (2007) Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007:95103PubMedCrossRefPubMedCentral

35.

Tang J, Kern TS (2011) Inflammation in diabetic retinopathy. Prog Retin Eye Res 30:343–358PubMedCrossRefPubMedCentral

36.

Ali TK, El-Remessy AB (2009) Diabetic retinopathy: current management and experimental therapeutic targets. Pharmacotherapy 29:182–192PubMedCrossRef

37.

Poulaki V, Qin W, Joussen AM et al (2002) Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest 109:805–815PubMedCrossRefPubMedCentral

38.

Nwariaku FE, Chang J, Zhu X et al (2002) The role of p38 map kinase in tumor necrosis factor-induced redistribution of vascular endothelial cadherin and increased endothelial permeability. Shock 18:82–85PubMedCrossRef

39.

Navaratna D, McGuire PG, Menicucci G, Das A (2007) Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 56:2380–2387PubMedCrossRef

40.

El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI (2006) Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168:235–244PubMedCrossRefPubMedCentral

41.

Wang YJ, Wang X, Lu JJ et al (2011) p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. J Neurosci 31:2292–2304PubMedCrossRef

42.

Rankin SL, Guy CS, Rahimtula M, Mearow KM (2008) Neurotrophin-induced upregulation of p75NTR via a protein kinase C-delta-dependent mechanism. Brain Res 1217:10–24PubMedCrossRef

43.

Huang H, Gandhi JK, Zhong X et al (2011) TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Investig Ophthalmol Vis Sci 52:1336–1344CrossRef

44.

Yang Y, Mao D, Chen X et al (2012) Decrease in retinal neuronal cells in streptozotocin-induced diabetic mice. Mol Vis 18:1411–1420PubMedPubMedCentral

45.

Shupe JM, Kristan DM, Austad SN, Stenkamp DL (2006) The eye of the laboratory mouse remains anatomically adapted for natural conditions. Brain Behav Evol 67:39–52PubMedCrossRefPubMedCentral

46.

Jain V, Ravindran E, Dhingra NK (2012) Differential expression of Brn3 transcription factors in intrinsically photosensitive retinal ganglion cells in mouse. J Comp Neurol 520:742–755PubMedCrossRef

47.

Martin PM, Roon P, van Ells TK, Ganapathy V, Smith SB (2004) Death of retinal neurons in streptozotocin-induced diabetic mice. Investig Ophthalmol Vis Sci 45:3330–3336CrossRef

48.

Reichardt LF (2006) Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 361:1545–1564PubMedCrossRefPubMedCentral

49.

Khursigara G, Orlinick JR, Chao MV (1999) Association of the p75 neurotrophin receptor with TRAF6. J Biol Chem 274:2597–2600PubMedCrossRef

Titel: Modulation of p75NTR prevents diabetes- and proNGF-induced retinal inflammation and blood–retina barrier breakdown in mice and rats
verfasst von: Barbara A. Mysona
Mohammed M. H. Al-Gayyar
Suraporn Matragoon
Mohammed A. Abdelsaid
Mona F. El-Azab
H. Uri Saragovi
Azza B. El-Remessy
Publikationsdatum: 01.10.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 10/2013
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-013-2998-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Modulation of p75^NTR prevents diabetes- and proNGF-induced retinal inflammation and blood–retina barrier breakdown in mice and rats